Literature DB >> 3183835

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis.

S H Abman1, J W Ogle, N Butler-Simon, C M Rumack, F J Accurso.   

Abstract

To determine the frequency of respiratory syncytial virus (RSV) as the cause of hospitalization for acute pulmonary exacerbations in young infants with cystic fibrosis (CF), and to assess the clinical effects of RSV infections, we prospectively followed 48 children with a diagnosis of CF after identification by newborn screening. At a mean follow-up age of 28.8 months (range 5 to 59), 18 infants (38%) had been hospitalized a total of 30 times for acute respiratory distress. At the time of admission, 18 infants (60%) were less than 12 months, 8 (27%) between 12 and 24 months, and 4 more than 2 years of age. The RSV was identified in seven hospitalized infants, as determined by fluorescent antibody, immunoassay, or culture. Before admission with RSV infection, one of the seven infants had chronic respiratory signs, none had Brasfield chest x-ray scores below 20, and a previous throat culture was positive for Staphylococcus aureus in one infant. Hospitalizations were prolonged (mean duration 22 days), and were characterized by significant morbidity, with three infants (43%) requiring mechanical ventilation and five infants (71%) requiring home oxygen therapy for persistent hypoxemia at discharge. At a mean follow-up age of 26 months, these infants more frequently have chronic respiratory signs (p less than 0.01) and lower chest radiograph scores (p less than 0.05) than other CF infants. These findings demonstrate that RSV is an important cause of early acute respiratory tract morbidity in young infants with CF, and suggest the need for studying new strategies to implement early and aggressive antiviral therapy in young infants with CF.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3183835     DOI: 10.1016/s0022-3476(88)80008-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  67 in total

1.  Viral infections: a role in the lung disease of cystic fibrosis?

Authors:  D J Shale
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

Review 2.  Cystic fibrosis, pathophysiological and clinical aspects.

Authors:  H J Neijens; M Sinaasappel; R de Groot; J C de Jongste; S E Overbeek
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

3.  Pediatric infections.

Authors:  N E Macdonald
Journal:  Can J Infect Dis       Date:  1992-03

4.  Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.

Authors:  Michael E Speer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 5.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

Review 6.  Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Authors:  Karen A Robinson; Olaide A Odelola; Ian J Saldanha
Journal:  Cochrane Database Syst Rev       Date:  2016-07-20

7.  Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).

Authors:  Ian Mitchell; S K Wong; B Paes; M Ruff; C Bjornson; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-04       Impact factor: 3.267

8.  Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?

Authors:  Candice Bjornson; Parco Chan; Abby Li; Bosco Paes; Krista L Lanctôt; Ian Mitchell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-19       Impact factor: 3.267

9.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 10.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.